GlassScriptPhysician profile
Matthew Olnes
NPI 1396760021
$729.14
in general payments reported to CMS, 2019-2025
15 companies · $380 in 2025
The $380 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $80.55 · 2023: $43.36 · 2024: $225 · 2025: $380.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $628 · Education: $21.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $627.59 |
| Education | $21.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $275.30 | 2022-2025 | Opdivo |
| Novartis Pharmaceuticals Corporation | $86.76 | 2023-2025 | |
| Pfizer INC. | $44.19 | 2024-2025 | |
| Jazz Pharmaceuticals INC. | $37.11 | 2025 | |
| Sobi, INC | $37.01 | 2024 | |
| Merck Sharp & Dohme LLC | $34.09 | 2025 | Lynparza, Keytruda, Welireg |
| Takeda Pharmaceuticals U.S.A., INC. | $32.04 | 2024 | Ninlaro |
| Blueprint Medicines Corporation | $29.95 | 2024 | Ayvakit |
| Astrazeneca Pharmaceuticals LP | $26.34 | 2025 | Imfinzi |
| Coherus Oncology, INC. | $25.64 | 2025 | Udenyca, Loqtorzi |
| Daiichi Sankyo INC. | $23.50 | 2025 | Enhertu |
| Mirati Therapeutics, INC. | $21.00 | 2023 | Krazati |
| Lilly USA, LLC | $18.95 | 2025 | Verzenio, Jaypirca |
| Abbvie INC. | $18.64 | 2025 | |
| Janssen Biotech, INC. | $18.62 | 2025 | Erleada |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Olnes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.